Three Years of Salvage IMRT for Prostate Cancer : Results of the Montpellier Cancer Center

Abstract EN

Background.

To assess the feasibility of salvage intensity-modulated radiation Therapy (IMRT) and to examine clinical outcome.

Patients and Methods.

57 patients were treated with salvage IMRT to the prostate bed in our center from January, 2007, to February, 2010.

The mean prescription dose was 68 Gy in 34 fractions.

Forty-four patients received concomitant androgen deprivation.

Results.

Doses to organs at risk were low without altering target volume coverage.

Salvage IMRT was feasible without any grade 3 or 4 acute gastrointestinal or urinary toxicity.

With a median follow-up of 21 months, one grade 2 urinary and 1 grade ≥2 rectal late toxicities were reported.

Biological relapse-free survival was 96.5% (2.3% (1/44) relapsed with androgen suppression and 7.7% (1/13) without).

Conclusion.

Salvage IMRT is feasible and results in low acute and chronic side-effects.

Longer follow-up is warranted to draw conclusions in terms of oncologic control.